About VantAI:
VantAI is rewriting the rules of drug discovery by making protein interactions programmable with Foundation ML led by luminary Michael Bronstein, a breakthrough data generation technology ready to scale, and an unmatched track record - $5B in deals including Bristol Myers Squibb, Johnson & Johnson, Sanofi and other leaders of the drug discovery world.
About the Role:
VantAI is looking for a highly motivated self-starter to coordinate and manage lab
operations in a new lab build out in Boston, MA. This person should bring a sense of
urgency and fiscal responsibility to enable the development of a highly sophisticated
data generation platform.
Key responsibilities:
Operational Oversight: Manage lab schedules, allocate equipment usage, and coordinate lab activities.
Resource Management: Oversee procurement (with help from Procurement Coordinator if available), maintain equipment maintenance schedules, manage budgets.
Compliance & Safety: Enforce EHS policies, coordinate with the Safety Officer, and ensure proper waste disposal.
Administrative Coordination: Liaise with finance/HR teams, manage vendor relationships, and handle service contracts.
Instrument maintenance: Coordinate PMs, repairs, and service visits with vendors.
Data & IT Coordination: Work with IT/data engineering teams to ensure mass spec PCs, data servers, and network storage remain functional, backed-up, and compliant with security protocols.
Requirements:
BSc in biology, chemistry, engineering, or associated subjects
+5 years experience managing lab operations
Experience with laboratory automation and associated considerations
Experience with permitting and EH&S regulations required
Experience with small startups and new lab buildouts a plus
Experience with mass spectrometers and managing large equipment service contracts a plus
Top Skills
What We Do
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. For more information, please visit http://www.vant.ai.
